ABSTRACT Herceptin is a humanized monoclonal antibody targeted against the extracellular domain of the _HER2_ oncogene, which is amplified and overexpressed in 10–34% of breast cancers.

Herceptin therapy provides effective treatment in _HER2_-positive metastatic breast cancer, although a favorable treatment response is not achieved in all cases. Here, we show that Herceptin

treatment induces a dose-dependent growth reduction in breast cancer cell lines with _HER2_ amplification, whereas nonamplified cell lines are practically resistant. Time-course analysis of

global gene expression patterns in amplified and nonamplified cell lines indicated a major change in transcript levels between 24 and 48 h of Herceptin treatment. A step-wise gene selection

processing and DNA repair, while cell adhesion mediators and known oncogenes, such as _c-FOS_ and _c-KIT_, were downregulated. These results provide additional clues to the downstream

effects of blocking the _HER2_ pathway in breast cancer and may provide new targets for more effective treatment. Access through your institution Buy or subscribe This is a preview of

subscription content, access via your institution ACCESS OPTIONS Access through your institution Subscribe to this journal Receive 50 print issues and online access $259.00 per year only

$5.18 per issue Learn more Buy this article * Purchase on SpringerLink * Instant access to full article PDF Buy now Prices may be subject to local taxes which are calculated during checkout

ADDITIONAL ACCESS OPTIONS: * Log in * Learn about institutional subscriptions * Read our FAQs * Contact customer support SIMILAR CONTENT BEING VIEWED BY OTHERS RADIOGENOMIC SIGNATURES REVEAL

MULTISCALE INTRATUMOUR HETEROGENEITY ASSOCIATED WITH BIOLOGICAL FUNCTIONS AND SURVIVAL IN BREAST CANCER Article Open access 25 September 2020 BREAST CANCER CONSENSUS SUBTYPES: A SYSTEM FOR

SUBTYPING BREAST CANCER TUMORS BASED ON GENE EXPRESSION Article Open access 12 October 2021 BREAST CANCER GENE EXPRESSION DATASETS DO NOT REFLECT THE DISEASE AT THE POPULATION LEVEL Article

Open access 25 August 2020 REFERENCES * Baselga J, Tripathy D, Mendelsohn J, Baughman S, Benz CC, Dantis L, Sklarin NT, Seidman AD, Hudis CA, Moore J, Rosen PP, Twaddell T, Henderson IC and

Norton L . (1996). _J. Clin. Oncol._, 14, 737–744. * Bolstad B, Irizarry R, Astrand M and Speed TA . (2003). _Bioinformatics_, 19, 185–193. * Carter P, Presta L, Gorman CM, Ridgway JB,

Henner D, Wong WL, Rowland AM, Kotts C, Carver ME and Shepard HM . (1992). _Proc. Natl. Acad. Sci. USA_, 89, 4285–4289. * Chen Y, Dougherty ER and Bittner ML . (1997). _J. Biomed. Optics_,

2, 364–374. * Cleveland W . (1979). _J. Am. Stat. Assoc._, 74, 829–836. * Cobleigh MA, Vogel CL, Tripathy D, Robert NJ, Scholl S, Fehrenbacher L, Wolter JM, Paton V, Shak S, Lieberman G and

Slamon DJ . (1999). _J. Clin. Oncol._, 17, 2639–2648. * Duan R, Xie W, Li X, McDougal A and Safe S . (2002). _Biochem. Biophys. Res. Commun._, 294, 384–394. * Eisen M, Spellman P, Brown P

and Botstein D . (1998). _Proc. Natl. Acad. Sci. USA_, 95, 14863–14868. * Furitsu T, Tsujimura T, Tono T, Ikeda H, Kitayama H, Koshimizu U, Sugahara H, Butterfield JH, Ashman LK, Kanayama Y,

Matsuzawa Y, Kitamura Y and Kanakura Y . (1993). _J. Clin. Invest._, 92, 1736–1744. * Hautaniemi S, Kauraniemi P, Rämö P, Yli-Harja O, Astola J and Kallioniemi A . (2003a). _A Strategy for

Identifying Class-Separating Genes in Drug-Treatment Microarray Data. Report 1_. Institute of Signal Processing, Tampere University of Technology: Finland, ISBN 952-15-1067-6. Google Scholar

  * Hautaniemi S, Yli-Harja O, Astola J, Kauraniemi P, Kallioniemi A, Wolf M, Ruiz J, Mousses S and Kallioniemi O-P . (2003b). _Mach. Learn._, 52, 45–66. * Hirota S, Isozaki K, Moriyama Y,

Hashimoto K, Nishida T, Ishiguro S, Kawano K, Hanada M, Kurata A, Takeda M, Muhammad Tunio G, Matsuzawa Y, Kanakura Y, Shinomura Y and Kitamura Y . (1998). _Science_, 279, 577–580. * Hyman

E, Kauraniemi P, Hautaniemi S, Wolf M, Mousses S, Rozenblum E, Ringner M, Sauter G, Monni O, Elkahloun A, Kallioniemi OP and Kallioniemi A . (2002). _Cancer Res._, 62, 6240–6245. *

Kauraniemi P, Bärlund M, Monni O and Kallioniemi A . (2001). _Cancer Res._, 61, 8235–8240. * Kohonen T (ed). (2001). _Self-Organizing Maps_, 3rd edn Springer: Heidelberg, Germany. Book 

Google Scholar  * Longley BJ, Reguera MJ and Ma Y . (2001). _Leuk. Res._, 25, 571–576. * Molina MA, Codony-Servat J, Albanell J, Rojo F, Arribas J and Baselga J . (2001). _Cancer Res._, 61,

4744–4749. * Monni O, Bärlund M, Mousses S, Kononen J, Sauter G, Heiskanen M, Paavola P, Avela K, Chen Y, Bittner ML and Kallioniemi A . (2001). _Proc. Natl. Acad. Sci. USA_, 98, 5711–5716.

* Mousses S, Bittner ML, Chen Y, Dougherty ER, Baxevanis A, Meltzer PS and Trent JM . (2000). _Functional Genomics: Gene Expression Analysis by cDNA Microarrays_, Livesey FJ and Hunt SP

(eds). Oxford University Press: Oxford, pp. 113–137. Google Scholar  * Ross JS and Fletcher JA . (1999). _Semin. Cancer Biol._, 9, 125–138. * Slamon DJ, Leyland-Jones B, Shak S, Fuchs H,

Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J and Norton L . (2001). _N. Engl. J. Med._, 344, 783–792. * van der Burg B, van Selm-Miltenburg AJ, de Laat SW and

van Zoelen EJ . (1989). _Mol. Cell. Endocrinol._, 64, 223–228. * Vesanto J, Himberg J, Alhoniemi E and Parhankangas J . (2000). _SOM Toolbox for Matlab 5. Technical Report A57_. Helsinki

University of Technology: Finland. Google Scholar  * Vogel CL, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, Fehrenbacher L, Slamon DJ, Murphy M, Novotny WF, Burchmore M, Shak S, Stewart

SJ and Press M . (2002). _J. Clin. Oncol._, 20, 719–726. * Wilding G, Lippman ME and Gelmann EP . (1988). _Cancer Res._, 48, 802–805. * Yakes FM, Chinratanalab W, Ritter CA, King W, Seelig S

and Arteaga CL . (2002). _Cancer Res._, 62, 4132–4141. * Yang Y, Dudoit S, Luu P and Speed T . (2001). _Microarrays: Optical Technologies and Informatics_, Bittner M, Chen Y, Dorsel A and

Dougherty E (eds). SPIE, Society for Optical Engineering: San Jose, CA, pp. 141–152. Book  Google Scholar  Download references ACKNOWLEDGEMENTS We thank Ms Kati Rouhento for excellent

technical assistance. This work was supported by the Academy of Finland, Foundation for Finnish Cancer Institute, the Medical Research Fund of the Tampere University Hospital, the Science

Fund of Tampere, as well as Finnish and Pirkanmaa Cultural Foundations. AUTHOR INFORMATION AUTHORS AND AFFILIATIONS * Laboratory of Cancer Genetics, Institute of Medical Technology,

University of Tampere and Tampere University Hospital, Tampere, FIN-33520, Finland Päivikki Kauraniemi & Anne Kallioniemi * Institute of Signal Processing, Tampere University of

Technology, Tampere, FIN-33101, Finland Sampsa Hautaniemi, Reija Autio & Jaakko Astola * Biomedicum Biochip Center, University of Helsinki, Biomedicum Helsinki, Helsinki, FIN-00290,

Finland Outi Monni * Cancer Genetics Branch, National Human Genome Research Institute, NIH, Bethesda, 20892, MD, USA Abdel Elkahloun Authors * Päivikki Kauraniemi View author publications

You can also search for this author inPubMed Google Scholar * Sampsa Hautaniemi View author publications You can also search for this author inPubMed Google Scholar * Reija Autio View author

publications You can also search for this author inPubMed Google Scholar * Jaakko Astola View author publications You can also search for this author inPubMed Google Scholar * Outi Monni

View author publications You can also search for this author inPubMed Google Scholar * Abdel Elkahloun View author publications You can also search for this author inPubMed Google Scholar *

Anne Kallioniemi View author publications You can also search for this author inPubMed Google Scholar CORRESPONDING AUTHOR Correspondence to Anne Kallioniemi. RIGHTS AND PERMISSIONS Reprints

and permissions ABOUT THIS ARTICLE CITE THIS ARTICLE Kauraniemi, P., Hautaniemi, S., Autio, R. _et al._ Effects of Herceptin treatment on global gene expression patterns in _HER2_-amplified

and nonamplified breast cancer cell lines. _Oncogene_ 23, 1010–1013 (2004). https://doi.org/10.1038/sj.onc.1207200 Download citation * Received: 26 May 2003 * Revised: 02 September 2003 *

Accepted: 10 September 2003 * Published: 01 December 2003 * Issue Date: 29 January 2004 * DOI: https://doi.org/10.1038/sj.onc.1207200 SHARE THIS ARTICLE Anyone you share the following link

with will be able to read this content: Get shareable link Sorry, a shareable link is not currently available for this article. Copy to clipboard Provided by the Springer Nature SharedIt

content-sharing initiative KEYWORDS * _HER2_ * herceptin * amplification * breast cancer * cDNA microarray